abstract: @entity6 is an increasingly common pathogen in healthcare settings globally. It is frequently resistant to multiple antimicrobial agents and there are recent reports on strains that are pandrug resistant. The aim of the study was to characterize the mechanisms of @entity5 resistance of A. baumannii strains from a nursing home in Zagreb and to genotype the strains. Antimicrobial susceptibility testing was performed by the broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI). PCR was used to detect genes encoding carbapenemases of groups A, B, and D and extended-spectrum b-lactamases. Genotyping of the strains was performed by rep-PCR. All strains were found to be resistant to @entity9 , @entity8 , @entity2 , @entity10 , @entity7 / @entity11 , @entity4 , @entity3 , and @entity1 . All, but one strain, were resistant to @entity0 . PCR revealed blaOXA-23 genes in 14, @entity12 in 5, and blaVIM in 11 strains. All strains positive for blaVIM genes coharbored blaOXA-23 genes. The 14 strains with OXA-23 belonged to ICL II, whereas the 5 strains positive for @entity12 belonged to ICL I. In contrast to hospitals where OXA-24/40-like b-lactamases and OXA-58 were the most prevalent, OXA-23-like b-lactamases are the dominant group in the nursing home. OXA-58-like b-lactamase, which is the most widespread group, was not found. Acquisition of blaMBL genes in A. baumannii strains was observed. Rep-PCR identified two clones. Two strains A10 and A13 were alocated to a novel sequence type ST 637. Nursing homes can act as a source of dissemination of blaOXA and blaMBL genes in the environment and the possible influx to the hospital environment.

title: Nursing Home as a Reservoir of @entity5 -Resistant XXXX .

answer: @entity6


abstract: @entity6 is an increasingly common pathogen in healthcare settings globally. It is frequently resistant to multiple antimicrobial agents and there are recent reports on strains that are pandrug resistant. The aim of the study was to characterize the mechanisms of @entity5 resistance of A. baumannii strains from a nursing home in Zagreb and to genotype the strains. Antimicrobial susceptibility testing was performed by the broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI). PCR was used to detect genes encoding carbapenemases of groups A, B, and D and extended-spectrum b-lactamases. Genotyping of the strains was performed by rep-PCR. All strains were found to be resistant to @entity9 , @entity8 , @entity2 , @entity10 , @entity7 / @entity11 , @entity4 , @entity3 , and @entity1 . All, but one strain, were resistant to @entity0 . PCR revealed blaOXA-23 genes in 14, @entity12 in 5, and blaVIM in 11 strains. All strains positive for blaVIM genes coharbored blaOXA-23 genes. The 14 strains with OXA-23 belonged to ICL II, whereas the 5 strains positive for @entity12 belonged to ICL I. In contrast to hospitals where OXA-24/40-like b-lactamases and OXA-58 were the most prevalent, OXA-23-like b-lactamases are the dominant group in the nursing home. OXA-58-like b-lactamase, which is the most widespread group, was not found. Acquisition of blaMBL genes in A. baumannii strains was observed. Rep-PCR identified two clones. Two strains A10 and A13 were alocated to a novel sequence type ST 637. Nursing homes can act as a source of dissemination of blaOXA and blaMBL genes in the environment and the possible influx to the hospital environment.

title: Nursing Home as a Reservoir of XXXX -Resistant @entity6 .

answer: @entity5


abstract: UNASSIGNED: Purpose To prospectively evaluate the performance of real-time ultrasonographic (US) shear-wave elastography (SWE) in the diagnosis of @entity1 in @entity0 with high and/or increasing @entity3 levels and/or abnormal digital rectal examination results. Materials and Methods After signing an informed consent form, @entity0 referred for transrectal prostate biopsy were enrolled in this prospective HIPAA-compliant two-center study, which was conducted with institutional review board approval. Transrectal US SWE of the prostate was performed after a conventional transrectal US examination and immediately before US-guided 12-core sextant biopsy. For each sextant, the maximum SWE value was measured and matched to the pathologic results of that sextant biopsy. The diagnostic performance of SWE was assessed at both @entity0 and sextant levels. The elasticity value maximizing the Youden index was used to derive sensitivity, specificity, positive predictive value ( @entity4 ), and negative predictive value (NPV). Results The elasticity values were matched to pathologic results for a total of 1040 peripheral zone sextants in 184 @entity0 . One hundred twenty-nine positive biopsy findings (size, >= 3 mm; Gleason score, >= 6) were identified in 68 @entity0 . The sextant-level sensitivity, specificity, @entity4 , NPV, and area under the receiver operating characteristic curve for SWE with a cutoff of 35 kPa for differentiating benign from malignant lesions were 96% (95% confidence interval [CI]: 95%, 97%), 85% (95% CI: 83%, 87%), 48% (95% CI: 46%, 50%), 99% (95% CI: 98%, 100%), and 95% (95% CI: 93%, 97%), respectively. Conclusion Use of a 35-kPa threshold at SWE may provide additional information for the detection and biopsy guidance of @entity1 , enabling a substantial reduction in the number of biopsies while ensuring that few peripheral zone @entity2 are missed.

title: XXXX : Diagnostic Performance of Real-time Shear-Wave Elastography.

answer: @entity1


abstract: UNASSIGNED: Infection with @entity3 has long been recognized in @entity0 . In recent years, @entity3 is an important cause of morbidity and mortality among adults and among those with underlying medical condition. Several cases of @entity2 and more fulminant disease similar to streptococcal @entity1 have recently been reported. We report here that 19 @entity3 strains were isolated from streptococcal @entity1 cases involving adult @entity0 in Japan between 2009 and 2013. The average age of the @entity0 was 66.3 years. At least one underlying disease was present in 47.4% (9/19) of the @entity0 . The most prevalent serotype among these strains was Ib. All serotype Ib strains belonged to clonal complex 10 and were ciprofloxacin resistant. In contrast, all strains were susceptible to penicillin G, ampicillin, cefazolin, cefotaxime, imipenem, panipenem, and linezolid. The characteristic type distributions of streptococcal @entity1 isolates differed between isolates obtained from vaginal swabs of @entity0 and @entity0 with invasive @entity2 .

title: Evaluation of streptococcal XXXX caused by group B @entity3 in adults in Japan between 2009 and 2013.

answer: @entity1


abstract: UNASSIGNED: Infection with @entity3 has long been recognized in @entity0 . In recent years, @entity3 is an important cause of morbidity and mortality among adults and among those with underlying medical condition. Several cases of @entity2 and more fulminant disease similar to streptococcal @entity1 have recently been reported. We report here that 19 @entity3 strains were isolated from streptococcal @entity1 cases involving adult @entity0 in Japan between 2009 and 2013. The average age of the @entity0 was 66.3 years. At least one underlying disease was present in 47.4% (9/19) of the @entity0 . The most prevalent serotype among these strains was Ib. All serotype Ib strains belonged to clonal complex 10 and were ciprofloxacin resistant. In contrast, all strains were susceptible to penicillin G, ampicillin, cefazolin, cefotaxime, imipenem, panipenem, and linezolid. The characteristic type distributions of streptococcal @entity1 isolates differed between isolates obtained from vaginal swabs of @entity0 and @entity0 with invasive @entity2 .

title: Evaluation of streptococcal @entity1 caused by group B XXXX in adults in Japan between 2009 and 2013.

answer: @entity3


abstract: UNASSIGNED: @entity4 is an @entity5 due to mutations of the @entity7 gene leading to toxic accumulation of galactose and derived metabolites. With the benefit of early diagnosis by neonatal screening and early therapy, the acute presentation of @entity4 can be prevented. However, despite early diagnosis and treatment, the long term outcome for these @entity0 is still unpredictable because they may go on to develop @entity1 , speech problems, neurological and/or @entity3 and, in females, @entity6 . The objectives of the current study were to report our experience with a group of galactosemic @entity0 identified through the neonatal screening programs in northeastern Italy during the last 30years. No @entity2 due to @entity4 complications occurred after the introduction of the neonatal screening program. However, despite the early diagnosis and dietary treatment, the @entity0 with @entity4 showed one or more long-term complications. A total of 18 different variations in the @entity7 gene were found in the @entity0 cohort: 12 missense, 2 frameshift, 1 nonsense, 1 deletion, 1 silent variation, and 1 intronic. Six ( @entity8 , @entity9 , @entity10 , @entity11 , @entity12 , @entity13 ) were new variations. The most common variation was @entity14 (12 alleles, 31.5%), followed by @entity15 (6 alleles, 15.7%) and @entity16 (6 alleles, 15.7%). The other variations comprised 1 or 2 alleles. In the @entity0 carrying a new mutation, the biochemical analysis of @entity7 activity in erythrocytes showed an activity of <1%. In silico analysis (SIFT, PolyPhen-2 and the computational analysis on the static protein structure) showed potentially damaging effects of the six new variations on the @entity7 protein, thus expanding the genetic spectrum of @entity7 variations in Italy. The study emphasizes the difficulty in establishing a genotype-phenotype correlation in @entity4 and underlines the importance of molecular diagnostic testing prior to making any treatment.

title: Clinical and molecular spectra in galactosemic @entity0 from neonatal screening in northeastern Italy: Structural and functional characterization of new variations in the XXXX ( @entity7 ) gene.

answer: @entity7


abstract: UNASSIGNED: @entity4 is an @entity5 due to mutations of the @entity7 gene leading to toxic accumulation of galactose and derived metabolites. With the benefit of early diagnosis by neonatal screening and early therapy, the acute presentation of @entity4 can be prevented. However, despite early diagnosis and treatment, the long term outcome for these @entity0 is still unpredictable because they may go on to develop @entity1 , speech problems, neurological and/or @entity3 and, in females, @entity6 . The objectives of the current study were to report our experience with a group of galactosemic @entity0 identified through the neonatal screening programs in northeastern Italy during the last 30years. No @entity2 due to @entity4 complications occurred after the introduction of the neonatal screening program. However, despite the early diagnosis and dietary treatment, the @entity0 with @entity4 showed one or more long-term complications. A total of 18 different variations in the @entity7 gene were found in the @entity0 cohort: 12 missense, 2 frameshift, 1 nonsense, 1 deletion, 1 silent variation, and 1 intronic. Six ( @entity8 , @entity9 , @entity10 , @entity11 , @entity12 , @entity13 ) were new variations. The most common variation was @entity14 (12 alleles, 31.5%), followed by @entity15 (6 alleles, 15.7%) and @entity16 (6 alleles, 15.7%). The other variations comprised 1 or 2 alleles. In the @entity0 carrying a new mutation, the biochemical analysis of @entity7 activity in erythrocytes showed an activity of <1%. In silico analysis (SIFT, PolyPhen-2 and the computational analysis on the static protein structure) showed potentially damaging effects of the six new variations on the @entity7 protein, thus expanding the genetic spectrum of @entity7 variations in Italy. The study emphasizes the difficulty in establishing a genotype-phenotype correlation in @entity4 and underlines the importance of molecular diagnostic testing prior to making any treatment.

title: Clinical and molecular spectra in galactosemic @entity0 from neonatal screening in northeastern Italy: Structural and functional characterization of new variations in the @entity7 ( XXXX ) gene.

answer: @entity7


abstract: UNASSIGNED: @entity4 is an @entity5 due to mutations of the @entity7 gene leading to toxic accumulation of galactose and derived metabolites. With the benefit of early diagnosis by neonatal screening and early therapy, the acute presentation of @entity4 can be prevented. However, despite early diagnosis and treatment, the long term outcome for these @entity0 is still unpredictable because they may go on to develop @entity1 , speech problems, neurological and/or @entity3 and, in females, @entity6 . The objectives of the current study were to report our experience with a group of galactosemic @entity0 identified through the neonatal screening programs in northeastern Italy during the last 30years. No @entity2 due to @entity4 complications occurred after the introduction of the neonatal screening program. However, despite the early diagnosis and dietary treatment, the @entity0 with @entity4 showed one or more long-term complications. A total of 18 different variations in the @entity7 gene were found in the @entity0 cohort: 12 missense, 2 frameshift, 1 nonsense, 1 deletion, 1 silent variation, and 1 intronic. Six ( @entity8 , @entity9 , @entity10 , @entity11 , @entity12 , @entity13 ) were new variations. The most common variation was @entity14 (12 alleles, 31.5%), followed by @entity15 (6 alleles, 15.7%) and @entity16 (6 alleles, 15.7%). The other variations comprised 1 or 2 alleles. In the @entity0 carrying a new mutation, the biochemical analysis of @entity7 activity in erythrocytes showed an activity of <1%. In silico analysis (SIFT, PolyPhen-2 and the computational analysis on the static protein structure) showed potentially damaging effects of the six new variations on the @entity7 protein, thus expanding the genetic spectrum of @entity7 variations in Italy. The study emphasizes the difficulty in establishing a genotype-phenotype correlation in @entity4 and underlines the importance of molecular diagnostic testing prior to making any treatment.

title: Clinical and molecular spectra in galactosemic XXXX from neonatal screening in northeastern Italy: Structural and functional characterization of new variations in the @entity7 ( @entity7 ) gene.

answer: @entity0


abstract: BACKGROUND: The possibility of validating biological macromolecules with locally disordered domains like RNA against solution properties is helpful to understand their function. In this work, we present a computational scheme for predicting global properties and mimicking the internal dynamics of RNA molecules in solution. A simple coarse-grained model with one bead per @entity3 and two types of intra-molecular interactions (elastic interactions and excluded volume interactions) is used to represent the RNA chain. The elastic interactions are modeled by a set of Hooke springs that form a minimalist elastic network. The Brownian dynamics technique is employed to simulate the time evolution of the RNA conformations. RESULTS: That scheme is applied to the 5S ribosomal RNA of @entity1 and the @entity0 @entity2 transfer RNA. From the Brownian trajectory, several solution properties (radius of gyration, translational diffusion coefficient, and a rotational relaxation time) are calculated. For the case of @entity0 @entity2 transfer RNA, the time evolution and the probability distribution of the inter-arm angle is also computed. CONCLUSIONS: The general good agreement between our results and some experimental data indicates that the model is able to capture the tertiary structure of RNA in solution. Our simulation results also compare quite well with other numerical data. An advantage of the scheme described here is the possibility of visualizing the real time macromolecular dynamics.

title: Prediction of solution properties and dynamics of RNAs by means of Brownian dynamics simulation of coarse-grained models: Ribosomal 5S RNA and XXXX transfer RNA.

answer: @entity2


abstract: OBJECTIVES: This study aimed to determine the pattern of hospital admissions and @entity0 outcomes in medical wards at Atbara Teaching Hospital in River Nile State, Sudan. METHODS: This retrospective cross-sectional study was conducted from August 2013 to July 2014 and included all @entity0 admitted to medical wards at the Atbara Teaching Hospital during the study period. Morbidity and mortality data was obtained from medical records. Diseases were categorised using the World Health Organization's @entity3 ( @entity3 ) coding system. RESULTS: A total of 2,614 @entity0 records were analysed. The age group with the highest admissions was the 56-65-year-old age group (19.4%) and the majority of @entity0 were admitted for one week or less (86.4%). Non- @entity4 constituted 71.8% of all cases. According to @entity3 classifications, @entity0 were admitted most frequently due to infectious or @entity8 (19.7%), followed by diseases of the circulatory (16.4%), digestive (16.4%) and genito-urinary (13.8%) systems. The most common diseases were @entity2 (16.4%), @entity6 (11.3%), @entity7 /peptic ulcer disease (9.8%), @entity5 (7.2%) and @entity1 (6.9%). The mortality rate was 4.7%. CONCLUSION: The burden of non- @entity4 was found to exceed that of @entity4 among @entity0 admitted to medical wards at the Atbara Teaching Hospital.

title: The Changing Pattern of Hospital Admission to Medical Wards: Burden of non- XXXX at a hospital in a developing country.

answer: @entity4


abstract: UNASSIGNED: @entity2 (FF) is widely used to lower blood lipids in clinical practice, but whether its protective effect on endothelium-dependent vasodilatation (EDV) in thoracic aorta is related with endoplasmic reticulum (ER) stress remains unknown. In this study, female Sprauge Dawley @entity1 were divided into standard chow diets (SCD), high-fat diets (HFD) and HFD plus FF treatment group (HFD  +  FF) randomly. The @entity1 of latter two groups were given HFD feeding for 5 months, then HFD  +  FF @entity1 were treated with FF (30  mg/kg, once daily) via gavage for another 2 months. The pathological and tensional changes, protein expression of eNOS, and ER stress related genes in thoracic aorta were measured. Then impacts of @entity3 (PA) and FF on EDV of thoracic aorta from normal female SD @entity1 were observed. Ultimately the expression of ER stress related genes were assessed in primary @entity0 aortic endothelial cells (MAEC) treated by @entity4 (FA) and PA. We found that FF treatment improved serum lipid levels and pathological changes in thoracic aorta, accompanied with decreased ER stress and increased phosphorylation of eNOS. FF pretreatment also improved EDV impaired by different concentrations of PA treatment. The dose- and time-dependent inhibition of cell proliferation by PA were inverted by FA pretreatment. Phosphorylation of eNOS and expression of ER stress related genes were all inverted by FA pretreatment in PA-treated MAEC. Our findings shows that @entity2 recovers damaged EDV by chronic HFD feeding and acute stimulation of PA, this effect is related with decreased ER stress and increased phosphorylation of eNOS.

title: Endoplasmic reticulum stress involved in high-fat diet and @entity3 -induced vascular damages and XXXX intervention.

answer: @entity2


abstract: UNASSIGNED: @entity2 (FF) is widely used to lower blood lipids in clinical practice, but whether its protective effect on endothelium-dependent vasodilatation (EDV) in thoracic aorta is related with endoplasmic reticulum (ER) stress remains unknown. In this study, female Sprauge Dawley @entity1 were divided into standard chow diets (SCD), high-fat diets (HFD) and HFD plus FF treatment group (HFD  +  FF) randomly. The @entity1 of latter two groups were given HFD feeding for 5 months, then HFD  +  FF @entity1 were treated with FF (30  mg/kg, once daily) via gavage for another 2 months. The pathological and tensional changes, protein expression of eNOS, and ER stress related genes in thoracic aorta were measured. Then impacts of @entity3 (PA) and FF on EDV of thoracic aorta from normal female SD @entity1 were observed. Ultimately the expression of ER stress related genes were assessed in primary @entity0 aortic endothelial cells (MAEC) treated by @entity4 (FA) and PA. We found that FF treatment improved serum lipid levels and pathological changes in thoracic aorta, accompanied with decreased ER stress and increased phosphorylation of eNOS. FF pretreatment also improved EDV impaired by different concentrations of PA treatment. The dose- and time-dependent inhibition of cell proliferation by PA were inverted by FA pretreatment. Phosphorylation of eNOS and expression of ER stress related genes were all inverted by FA pretreatment in PA-treated MAEC. Our findings shows that @entity2 recovers damaged EDV by chronic HFD feeding and acute stimulation of PA, this effect is related with decreased ER stress and increased phosphorylation of eNOS.

title: Endoplasmic reticulum stress involved in high-fat diet and XXXX -induced vascular damages and @entity2 intervention.

answer: @entity3


abstract: A method of local @entity3 with @entity2 of one or more of the major vessels of the neck is described. Ten clinical cases have been operated upon, and much has been learned of the operative difficulties including an increased operating time and a high complication rate. There were four post-operative deaths, in one (case 1) there was some evidence that the technique protected the perfused part of the brain from anoxic damage. In case 9 the method itself caused particularly bad operating conditions and eventually the @entity0 died. Case 2 and case 4, like case 1, were @entity0 who were severely ill and who might well have died whatever technique had been used in operating upon them. Of the survivors, one @entity0 (case 3) had a post-operative intracerebral clot which developed during closure and another (case 6) had an intracerebral clot which required removal after 24 hours. Another @entity0 (case 8) had some delay in return to full mental function. In the light of this experience we cannot regard the method in its present form as satisfactory for general use. In our view, its further development requires the discovery of a more effective means of neutralizing the anticoagulants, or doing without anticoagulants altogether. It is also necessary to develop a method of monitoring parts of the brain distant from those directly perfused to give warning of threatened @entity1 . Until such time as these problems can be solved we have returned to other procedures but are publishing our results in the hope that other workers will be able to improve upon them.

title: Report of 10 operations under local XXXX .

answer: @entity3


abstract: UNASSIGNED: Purpose. To evaluate the molecular pathways that operate in the early phase of acute @entity6 by studying gene expression profiles of peripheral blood mononuclear cells (PBMCs) subpopulations including @entity4 + B cells, @entity5 + macrophages, @entity2 + and @entity3 + T cells. Methods. PBMC subpopulations were obtained from 11 @entity1 @entity0 within 96 hours of the acute onset of the first demyelinating event of ON and from 14 healthy subjects. Gene expression analysis was performed on samples from 6 ON @entity0 and 9 healthy subjects (Affymetrix). Data was analyzed using Partek software and most informative genes (MIGs) were defined with p<0.01 and fold change >2.0. Verification of key MIGs was done by QRT-PCR and Western blot. Functional assay to test antigen presentation ability of B cells was performed. Results. Significantly differentiating gene expression signatures consisting of 467, 55, and 55 MIGs respective of @entity4 +, @entity5 + and @entity2 + cells were identified between ON and healthy subjects. No MIGs was detected for @entity3 + cells. The major involvement of @entity4 + B cells in the early stage of ON was characterized by enrichment of genes involved in activation of immune mechanisms (p=3.2*10-25 to 2.5*10-3) including cellular immune response (p=7.1*10-12), B cells cellular growth and proliferation (p=1.0*10-7), activation of immune cells trafficking pathways (p=5.4*10-15 to 2.0*10-3), and stimulation of antigen presentation (p=8.9*10-11). Conclusions. Our findings demonstrate that @entity4 + B cells play a significant role in the pathogenesis of the first demyelinating event of acute ON and suggest their role as possible target for immunomodulation.

title: The role of B cells in the onset of the first demyelinating event of XXXX .

answer: @entity6


abstract: IMPORTANCE: Traumatic brain injury ( @entity5 ) is a significant public health concern that affects individuals in all demographics. With increasing interest in the medical and public communities, understanding the inflammatory mechanisms that drive the pathologic and consequent cognitive outcomes can inform future research and clinical decisions for @entity0 with @entity5 . OBJECTIVES: To review known inflammatory mechanisms in @entity5 and to highlight clinical trials and neuroprotective therapeutic manipulations of pathologic and inflammatory mechanisms of @entity5 . EVIDENCE REVIEW: We searched articles in PubMed published between 1960 and August 1, 2014, using the following keywords: traumatic @entity8 , @entity4 , @entity2 , astrocytes, microglia, monocytes, macrophages, neutrophils, T cells, reactive @entity1 species, alarmins, danger-associated molecular patterns, purinergic receptors, neuroprotection, and clinical trials. Previous clinical trials or therapeutic studies that involved manipulation of the discussed mechanisms were considered for inclusion. The final list of selected studies was assembled based on novelty and direct relevance to the primary focus of this review. FINDINGS: Traumatic brain injury is a diverse group of sterile injuries induced by primary and secondary mechanisms that give rise to cell @entity6 , @entity2 , and @entity3 in @entity0 of all demographics. Pathogenesis is driven by complex, interacting mechanisms that include reactive @entity1 species, ion channel and gap junction signaling, purinergic receptor signaling, excitotoxic neurotransmitter signaling, perturbations in @entity7 homeostasis, and damage-associated molecular pattern molecules, among others. Central nervous system resident and peripherally derived inflammatory cells respond to @entity5 and can provide neuroprotection or participate in @entity4 reactions. The exact contribution of inflammatory cells to a @entity5 is dictated by their anatomical positioning as well as the local cues to which they are exposed. CONCLUSIONS AND RELEVANCE: The mechanisms that drive @entity5 development as well as those that promote repair are exceedingly complex and often superimposed. Because pathogenic mechanisms can diversify over time or even differ based on the @entity4 , it is important that neuroprotective therapeutics be developed and administered with these variables in mind. Due to its complexity, @entity5 has proven particularly challenging to treat; however, a number of promising therapeutic approaches are now under pre-clinical development, and recent clinical trials have even yielded a few successes. Given the worldwide impact of @entity5 on the @entity0 population, it is imperative that research remains active in this area and that we continue to develop therapeutics to improve outcome in afflicted @entity0 .

title: XXXX and neuroprotection in traumatic brain injury.

answer: @entity2


abstract: PURPOSE: The purpose of this study was to evaluate the safety and efficacy of low-dose-intensity bevacizumab and weekly @entity10 as salvage treatment for @entity0 with @entity8 - and @entity11 -resistant advanced @entity1 . METHODS: Fifty-two @entity0 with @entity8 - and @entity11 -resistant advanced @entity1 received bevacizumab 5  mg/Kg days 1 and 15; @entity10 60  mg/m(2) days 1, 8 and 15. The combined therapy was repeated every 28  days, up to six cycles. RESULTS: A total of 230 cycles of bevacizumab combined with @entity10 were administrated to 52 @entity0 . Among the 52 @entity0 , 22 @entity0 achieved partial response (42.3  %); 12 @entity0 had stable disease (23.1  %) and 18 @entity0 experienced disease progression (34.6  %). The median progression-free survival and the median overall survival were 8.0  months (95  % confidence interval: 6.74-9.26  months) and 13.8  months (95  % confidence interval: 11.97-15.63  months), respectively. The most frequent grade 3-4 hematologic @entity3 were @entity9 (11.5  %) and @entity7 (3.8  %). The non-hematologic @entity3 included grade 3 @entity4 (3.8  %) and @entity2 (3.8  %). Two @entity0 (3.8  %) were confirmed with deep vein @entity6 . @entity9 , symptomatic @entity5 and gastrointestinal perforation were not observed in this study. CONCLUSIONS: The combination of low-dose-intensity bevacizumab and weekly @entity10 was an effective and safe regimen for @entity0 with @entity8 - and @entity11 -resistant @entity1 .

title: Low-dose-intensity bevacizumab with weekly XXXX for @entity8 - and @entity11 -resistant @entity1 .

answer: @entity10


abstract: PURPOSE: The purpose of this study was to evaluate the safety and efficacy of low-dose-intensity bevacizumab and weekly @entity10 as salvage treatment for @entity0 with @entity8 - and @entity11 -resistant advanced @entity1 . METHODS: Fifty-two @entity0 with @entity8 - and @entity11 -resistant advanced @entity1 received bevacizumab 5  mg/Kg days 1 and 15; @entity10 60  mg/m(2) days 1, 8 and 15. The combined therapy was repeated every 28  days, up to six cycles. RESULTS: A total of 230 cycles of bevacizumab combined with @entity10 were administrated to 52 @entity0 . Among the 52 @entity0 , 22 @entity0 achieved partial response (42.3  %); 12 @entity0 had stable disease (23.1  %) and 18 @entity0 experienced disease progression (34.6  %). The median progression-free survival and the median overall survival were 8.0  months (95  % confidence interval: 6.74-9.26  months) and 13.8  months (95  % confidence interval: 11.97-15.63  months), respectively. The most frequent grade 3-4 hematologic @entity3 were @entity9 (11.5  %) and @entity7 (3.8  %). The non-hematologic @entity3 included grade 3 @entity4 (3.8  %) and @entity2 (3.8  %). Two @entity0 (3.8  %) were confirmed with deep vein @entity6 . @entity9 , symptomatic @entity5 and gastrointestinal perforation were not observed in this study. CONCLUSIONS: The combination of low-dose-intensity bevacizumab and weekly @entity10 was an effective and safe regimen for @entity0 with @entity8 - and @entity11 -resistant @entity1 .

title: Low-dose-intensity bevacizumab with weekly @entity10 for @entity8 - and XXXX -resistant @entity1 .

answer: @entity11


abstract: PURPOSE: The purpose of this study was to evaluate the safety and efficacy of low-dose-intensity bevacizumab and weekly @entity10 as salvage treatment for @entity0 with @entity8 - and @entity11 -resistant advanced @entity1 . METHODS: Fifty-two @entity0 with @entity8 - and @entity11 -resistant advanced @entity1 received bevacizumab 5  mg/Kg days 1 and 15; @entity10 60  mg/m(2) days 1, 8 and 15. The combined therapy was repeated every 28  days, up to six cycles. RESULTS: A total of 230 cycles of bevacizumab combined with @entity10 were administrated to 52 @entity0 . Among the 52 @entity0 , 22 @entity0 achieved partial response (42.3  %); 12 @entity0 had stable disease (23.1  %) and 18 @entity0 experienced disease progression (34.6  %). The median progression-free survival and the median overall survival were 8.0  months (95  % confidence interval: 6.74-9.26  months) and 13.8  months (95  % confidence interval: 11.97-15.63  months), respectively. The most frequent grade 3-4 hematologic @entity3 were @entity9 (11.5  %) and @entity7 (3.8  %). The non-hematologic @entity3 included grade 3 @entity4 (3.8  %) and @entity2 (3.8  %). Two @entity0 (3.8  %) were confirmed with deep vein @entity6 . @entity9 , symptomatic @entity5 and gastrointestinal perforation were not observed in this study. CONCLUSIONS: The combination of low-dose-intensity bevacizumab and weekly @entity10 was an effective and safe regimen for @entity0 with @entity8 - and @entity11 -resistant @entity1 .

title: Low-dose-intensity bevacizumab with weekly @entity10 for @entity8 - and @entity11 -resistant XXXX .

answer: @entity1


abstract: PURPOSE: The purpose of this study was to evaluate the safety and efficacy of low-dose-intensity bevacizumab and weekly @entity10 as salvage treatment for @entity0 with @entity8 - and @entity11 -resistant advanced @entity1 . METHODS: Fifty-two @entity0 with @entity8 - and @entity11 -resistant advanced @entity1 received bevacizumab 5  mg/Kg days 1 and 15; @entity10 60  mg/m(2) days 1, 8 and 15. The combined therapy was repeated every 28  days, up to six cycles. RESULTS: A total of 230 cycles of bevacizumab combined with @entity10 were administrated to 52 @entity0 . Among the 52 @entity0 , 22 @entity0 achieved partial response (42.3  %); 12 @entity0 had stable disease (23.1  %) and 18 @entity0 experienced disease progression (34.6  %). The median progression-free survival and the median overall survival were 8.0  months (95  % confidence interval: 6.74-9.26  months) and 13.8  months (95  % confidence interval: 11.97-15.63  months), respectively. The most frequent grade 3-4 hematologic @entity3 were @entity9 (11.5  %) and @entity7 (3.8  %). The non-hematologic @entity3 included grade 3 @entity4 (3.8  %) and @entity2 (3.8  %). Two @entity0 (3.8  %) were confirmed with deep vein @entity6 . @entity9 , symptomatic @entity5 and gastrointestinal perforation were not observed in this study. CONCLUSIONS: The combination of low-dose-intensity bevacizumab and weekly @entity10 was an effective and safe regimen for @entity0 with @entity8 - and @entity11 -resistant @entity1 .

title: Low-dose-intensity bevacizumab with weekly @entity10 for XXXX - and @entity11 -resistant @entity1 .

answer: @entity8


abstract: BACKGROUND/AIMS: The endocannabinoid system can exert beneficial effects on @entity4 , and @entity5 ( @entity5 ) agonists may represent a new therapeutic approach in @entity1 ( @entity1 ). A functional @entity5 @entity6 polymorphism ( @entity7 ) in the @entity5 gene has been shown to affect the immunomodulating properties of the @entity5 receptor. We sought to investigate whether the functional @entity5 @entity6 polymorphism ( @entity7 ) is associated with @entity1 susceptibility in a Turkish clinical sample. MATERIALS AND METHODS: A total of 202 @entity1 @entity0 , comprising 101 @entity2 ( @entity2 ) @entity0 and 101 @entity3 ( @entity3 ) @entity0 , and 101 healthy controls were included in the study. The @entity5 @entity6 polymorphism was genotyped using real-time PCR. RESULTS: There were no significant differences in the genotype frequencies of the three study groups. The odds ratio of the minor Q allele for @entity2 relative to the common R allele was not significant (OR =1.02, 95% CI =0.67-1.56, p=0.99). Similarly, the odds ratio of the minor Q allele for @entity3 relative to the common R allele did not reach statistical significance (OR =1.10, 95% CI =0.72-1.68, p=0.75). Moreover, the genotype frequencies did not show any significant association with the disease extent in either @entity2 (p= 0.71) or @entity3 @entity0 (p=0.59). CONCLUSION: These pilot findings suggest that @entity5 @entity6 polymorphism does not play a major role in genetic susceptibility to @entity1 or in its disease phenotypes among Turkish subjects.

title: No association between the functional cannabinoid receptor type 2 @entity6 variants and XXXX in Turkish subjects.

answer: @entity1


abstract: BACKGROUND/AIMS: The endocannabinoid system can exert beneficial effects on @entity4 , and @entity5 ( @entity5 ) agonists may represent a new therapeutic approach in @entity1 ( @entity1 ). A functional @entity5 @entity6 polymorphism ( @entity7 ) in the @entity5 gene has been shown to affect the immunomodulating properties of the @entity5 receptor. We sought to investigate whether the functional @entity5 @entity6 polymorphism ( @entity7 ) is associated with @entity1 susceptibility in a Turkish clinical sample. MATERIALS AND METHODS: A total of 202 @entity1 @entity0 , comprising 101 @entity2 ( @entity2 ) @entity0 and 101 @entity3 ( @entity3 ) @entity0 , and 101 healthy controls were included in the study. The @entity5 @entity6 polymorphism was genotyped using real-time PCR. RESULTS: There were no significant differences in the genotype frequencies of the three study groups. The odds ratio of the minor Q allele for @entity2 relative to the common R allele was not significant (OR =1.02, 95% CI =0.67-1.56, p=0.99). Similarly, the odds ratio of the minor Q allele for @entity3 relative to the common R allele did not reach statistical significance (OR =1.10, 95% CI =0.72-1.68, p=0.75). Moreover, the genotype frequencies did not show any significant association with the disease extent in either @entity2 (p= 0.71) or @entity3 @entity0 (p=0.59). CONCLUSION: These pilot findings suggest that @entity5 @entity6 polymorphism does not play a major role in genetic susceptibility to @entity1 or in its disease phenotypes among Turkish subjects.

title: No association between the functional cannabinoid receptor type 2 XXXX variants and @entity1 in Turkish subjects.

answer: @entity6


abstract: Thoracolumbar spine @entity3 are common injuries that can result in significant disability, @entity1 . Controversies exist regarding the appropriate radiological investigations, the indications for surgical management and the timing, approach and type of surgery. This review provides an overview of the epidemiology, biomechanical principles, radiological and clinical evaluation, classification and management principles. Literature review of all relevant articles published in PubMed covering thoracolumbar spine @entity3 with or without @entity1 was performed. The search terms used were thoracolumbar, thoracic, lumbar, @entity3 , @entity2 and management. All relevant articles and abstracts covering thoracolumbar spine @entity3 with and without @entity1 were reviewed. Biomechanically the thoracolumbar spine is predisposed to a higher incidence of @entity5 . Computed tomography provides adequate bony detail for assessing spinal stability while magnetic resonance imaging shows injuries to soft tissues (posterior ligamentous complex [PLC]) and @entity0 . Different classification systems exist and the most recent is the AO spine knowledge forum classification of thoracolumbar @entity2 . Treatment includes both nonoperative and operative methods and selected based on the degree of @entity2 , neurological involvement, presence of associated injuries and the integrity of the PLC. Significant advances in imaging have helped in the better understanding of thoracolumbar @entity3 , including information on canal morphology and injury to soft tissue structures. The ideal classification that is simple, comprehensive and guides management is still elusive. Involvement of three columns, progressive @entity1 , significant @entity4 and canal compromise with @entity1 are accepted indications for surgical stabilization through anterior, posterior or combined approaches.

title: Management of thoracolumbar spine XXXX : An overview.

answer: @entity2


abstract: AIM: To ascertain pathologic stage as a prognostic indicator for @entity1 @entity0 receiving preoperative chemoradiotherapy (PCRT). METHODS: @entity0 with mid- and low @entity2 (magnetic resonance imaging - based clinical stage II or III) between 2000 and 2009 and treated with curative radical resection were identified. @entity0 were divided into two groups: PCRT and No-PCRT. Recurrence-free survival (RFS) was examined according to pathologic stage and addition of adjuvant treatment. RESULTS: Overall, 894 @entity0 were identified. Of these, 500 @entity0 received PCRT. Adjuvant chemotherapy was delivered to 81.5% of the No-PCRT and 94.8% of the PCRT @entity0 . Adjuvant radiotherapy was given to 29.4% of the @entity0 in the No PCRT group. The 5-year RFS for the No-PCRT group was 92.6% for Stage   I, 83.3% for Stage II, and 72.9% for Stage III. The 5-year RFS for the PCRT group was 95.2% for yp Stage 0, 91.7% for yp Stage   I, 73.9% for yp Stage II, and 50.7% for yp Stage III. CONCLUSION: Pathologic stage can predict prognosis in PCRT @entity0 . 5-year RFS is significantly lower among PCRT @entity0 than No-PCRT @entity0 in pathologic stage II and III. These results should be taken into account when considering adjuvant treatment for @entity0 treated with PCRT.

title: Impression of prognosis regarding pathologic stage after preoperative chemoradiotherapy in XXXX .

answer: @entity1


abstract: UNASSIGNED: Background and study aims: The use of covered self-expandable metallic stents (cSEMS) in benign biliary indications is evolving. The aim of the study was to assess the safety and feasibility of cSEMS compared with multiple plastic stents in the treatment of @entity1 ( @entity1 ) caused by @entity2 . @entity0 and methods: This was a prospective, multicenter, randomized study of 60 @entity0 with @entity1 caused by @entity2 . All @entity0 received an initial plastic stent before randomization. At randomization, the stent was replaced either with a single cSEMS or three plastic stents. After 3 months, the position of the cSEMS was checked or another three plastic stents were added. At 6 months after randomization, all stents were removed. Clinical follow-up including abdominal ultrasound and laboratory tests were performed at 6 months and 2 years after stent removal. Results: Two @entity0 dropped out of the cSEMS group before stent removal. In April 2014, the median follow-up was 40 months (range 1-66 months). The 2-year, stricture-free success rate was 90% (95% confidence interval [CI] 72%-97%) in the plastic stent group and 92% (95%CI 70%-98%) in the cSEMS group (P=0.405). There was one late recurrence in the plastic stent group 50 months after stent removal. Stent migration occurred three times (10%) in the plastic stent group and twice in the cSEMS group (7%; P=1.000). Conclusion: A 6-month treatment with either six 10-Fr plastic stents or with one 10-mm cSEMS produced good long-term relief of @entity1 caused by @entity2 .Study registered at ClinicalTrials.gov (NCT01085747).

title: Randomized multicenter study of multiple plastic stents vs. covered self-expandable metallic stent in the treatment of XXXX in @entity2 .

answer: @entity1


abstract: UNASSIGNED: Background and study aims: The use of covered self-expandable metallic stents (cSEMS) in benign biliary indications is evolving. The aim of the study was to assess the safety and feasibility of cSEMS compared with multiple plastic stents in the treatment of @entity1 ( @entity1 ) caused by @entity2 . @entity0 and methods: This was a prospective, multicenter, randomized study of 60 @entity0 with @entity1 caused by @entity2 . All @entity0 received an initial plastic stent before randomization. At randomization, the stent was replaced either with a single cSEMS or three plastic stents. After 3 months, the position of the cSEMS was checked or another three plastic stents were added. At 6 months after randomization, all stents were removed. Clinical follow-up including abdominal ultrasound and laboratory tests were performed at 6 months and 2 years after stent removal. Results: Two @entity0 dropped out of the cSEMS group before stent removal. In April 2014, the median follow-up was 40 months (range 1-66 months). The 2-year, stricture-free success rate was 90% (95% confidence interval [CI] 72%-97%) in the plastic stent group and 92% (95%CI 70%-98%) in the cSEMS group (P=0.405). There was one late recurrence in the plastic stent group 50 months after stent removal. Stent migration occurred three times (10%) in the plastic stent group and twice in the cSEMS group (7%; P=1.000). Conclusion: A 6-month treatment with either six 10-Fr plastic stents or with one 10-mm cSEMS produced good long-term relief of @entity1 caused by @entity2 .Study registered at ClinicalTrials.gov (NCT01085747).

title: Randomized multicenter study of multiple plastic stents vs. covered self-expandable metallic stent in the treatment of @entity1 in XXXX .

answer: @entity2


abstract: UNASSIGNED: Context     @entity3 is the leading cause of @entity2 , affecting 15% of Americans older than 65 y and costing  43 billion each year. The current mental health service system for seniors, particularly for the population hospitalized in acute inpatient @entity1 units, is fragmented because of poor funding and a shift to a transitory health care paradigm, leading to inadequate treatment modalities, questionable quality of care, and lack of research demonstrating the superiority of a particular treatment. These issues are likely to lead to a public health crisis in the coming years. Objective     To investigate the effectiveness of combining exercise and psychotherapy in improving acute @entity3 symptoms among older adults who were receiving treatment in an inpatient @entity1 unit. Design     Based on rolling admissions, inpatients were randomly assigned to 1 of 3 treatment groups. The study was blinded and controlled. Setting     This study took place in inpatient @entity1 units at the Loma Linda University's Behavioral Medicine Center (LLUBMC) in Redlands, California. @entity0     @entity0 were 78 inpatients, aged 50-89 y. Intervention     @entity0 in the simultaneous exercise and psychotherapy (STEP) group (n = 26) took part in exercise and received psychotherapy for 30 min per session, whereas those in the TALK group (n = 26) received individual psychotherapy for 30 min per session. @entity0 in the control group (n = 26) served as a comparison group, receiving standard therapy. Outcome Measures     The effects of the interventions were determined by assessing differences from baseline to postintervention in the symptomatology of all 3 groups. The research team also administered the Behavioral and Symptom Identification Scale (BASIS-32) and the Geriatric @entity3 Scale (GDS) pre- and postintervention. Results     At posttest, the STEP group (M = 4.24, SE = 0.62) had a better response than the TALK group (M = 11.34, SE = 0.62, P < .001), which in turn showed greater improvement than the control group (M = 14.84, SE = 0.62, P < .001). Overall, these results indicate that @entity0 ' posttreatment @entity3 scores were significantly lower in those receiving the STEP treatment compared with those receiving individual psychotherapy only or standard care. Conclusion     A short-term exercise program consisting of 30 min of walking in conjunction with individual psychotherapy was an effective intervention for @entity3 among older adults in inpatient @entity1 units.

title: The Effects of Simultaneous Exercise and Psychotherapy on XXXX in Inpatient, Psychiatric Older Adults.

answer: @entity3


abstract: BACKGROUND: The effect of topical mometasone for @entity2 treatment is well established. Nevertheless, the influence of atopy on this treatment remains ill defined. OBJECTIVE: This study aims to compare the effects of topical mometasone furoate treatment on the adenoid tissue between atopic and nonatopic @entity0 . METHODS: Fifty-one @entity0 with obstructive respiratory complaints underwent a semistructured clinical questionnaire on nasal symptoms, prick test, and nasoendoscopy. Nasoendoscopic images were digitalized, and both adenoid and nasopharyngeal areas were measured in pixels; the relative adenoid/nasopharyngeal area was calculated. @entity0 were initially treated for 40 days with nasal saline solution. In a subsequent 40-day period, topical mometasone furoate (total dose, 100  g/day) was used. RESULTS: Topical mometasone significantly improved nasal obstruction, snoring, and @entity1 and also significantly reduced the adenoid tissue area related to the nasopharynx (p < 0.0001). Treatment with this glucocorticoid was not influenced by atopy, neither for symptoms nor for adenoid area. CONCLUSION: Topical mometasone furoate significantly reduced the adenoid tissue area and led to a supplementary improvement of nasal symptoms. This improvement was similar for atopic and nonatopic @entity0 .

title: Does atopy influence the effectiveness of treatment of XXXX with mometasone furoate?

answer: @entity2


abstract: BACKGROUND: The mechanisms regulating @entity2 ( @entity2 ) are not well understood, although poor nutritional status and "intense" breastfeeding behaviors are associated with longer durations. OBJECTIVES: This study was designed primarily to investigate the hypothesis that higher body fat and @entity1 concentrations are related to shorter @entity2 in healthy, lactating US @entity0 . Nutrient intake, breastfeeding behaviors, prolactin, and insulin levels were also evaluated. METHODS: Fasting serum was collected during the third trimester of pregnancy, at 2 and 4 weeks postpartum, and every 4 weeks until the occurrence of the first postpartum menses. Body composition and breastfeeding behaviors were assessed at the same times postpartum. @entity0 (n = 13) were categorized based on initial percentage body fat and timing of first postpartum menses. RESULTS: There were no consistent relationships between body composition, @entity1 , or breastfeeding behaviors and duration of @entity2 . However, there was an interaction (P = .005) between ovulation group and time on adiposity; earlier ovulating @entity0 had less percentage body fat in early lactation than did later ovulating @entity0 . There was also an interaction (P = .1) between ovulation group and time postpartum on @entity1 , such that @entity1 concentrations tended to be greater in later than earlier ovulating groups beginning at 12 weeks postpartum. CONCLUSION: In summary, although baseline percentage body fat and @entity1 were not related to duration of @entity2 , fertility returned earlier in @entity0 who lost greater percentage body fat during the early postpartum period.

title: Loss of Body Fat and Associated Decrease in XXXX in Early Lactation Are Related to Shorter Duration of Postpartum Anovulation in Healthy US @entity0 .

answer: @entity1


abstract: BACKGROUND: The mechanisms regulating @entity2 ( @entity2 ) are not well understood, although poor nutritional status and "intense" breastfeeding behaviors are associated with longer durations. OBJECTIVES: This study was designed primarily to investigate the hypothesis that higher body fat and @entity1 concentrations are related to shorter @entity2 in healthy, lactating US @entity0 . Nutrient intake, breastfeeding behaviors, prolactin, and insulin levels were also evaluated. METHODS: Fasting serum was collected during the third trimester of pregnancy, at 2 and 4 weeks postpartum, and every 4 weeks until the occurrence of the first postpartum menses. Body composition and breastfeeding behaviors were assessed at the same times postpartum. @entity0 (n = 13) were categorized based on initial percentage body fat and timing of first postpartum menses. RESULTS: There were no consistent relationships between body composition, @entity1 , or breastfeeding behaviors and duration of @entity2 . However, there was an interaction (P = .005) between ovulation group and time on adiposity; earlier ovulating @entity0 had less percentage body fat in early lactation than did later ovulating @entity0 . There was also an interaction (P = .1) between ovulation group and time postpartum on @entity1 , such that @entity1 concentrations tended to be greater in later than earlier ovulating groups beginning at 12 weeks postpartum. CONCLUSION: In summary, although baseline percentage body fat and @entity1 were not related to duration of @entity2 , fertility returned earlier in @entity0 who lost greater percentage body fat during the early postpartum period.

title: Loss of Body Fat and Associated Decrease in @entity1 in Early Lactation Are Related to Shorter Duration of Postpartum Anovulation in Healthy US XXXX .

answer: @entity0


abstract: UNASSIGNED: The use of biocompatible chemical compounds that enhance plant disease resistance through Induced Resistance (IR) is an innovative strategy to improve the yield and quality of crops. Phosphites (Phi), inorganic salts of @entity7 , are environment friendly, and have been described to induce disease control. Phi, similar to other plant inductors, are thought to be effective against different types of biotic and abiotic stress, and it is assumed that the underlying signaling pathways probably overlap and interact. The signaling pathways triggered by UV-B radiation, for instance, are known to crosstalk with other signaling routes that respond that biotic stress. In the present work, the effect of @entity9 (KPhi) pre-treatment on UV-B stress tolerance was evaluated in @entity4 leaves. Plants were treated with KPhi and, after 3 days, exposed to 2  h/day of UV-B (1.5 Watt m(-2)) for 0, 3 and 6 days. KPhi pre-treatment had a beneficial effect on two photosynthetic parameters, specifically chlorophyll content and expression of the @entity10 gene. @entity0 caused by UV-B was also prevented by KPhi. A decrease in the accumulation of @entity2 ( @entity3 ) in leaves and an increase in @entity6 @entity8 ( @entity8 ) and @entity1 dismutase (SOD) activities were also observed. In addition, the expression levels of a gene involved in @entity5 synthesis increased in UV-B-stressed plants only when pre-treated with KPhi. Finally, accumulation of glucanases and chitinases was induced by UV-B stress and markedly potentiated by KPhi pre-treatment. Altogether, this is the first report that shows a contribution of KPhi in UV-B stress tolerance in @entity4 plants.

title: Potassium phosphite increases tolerance to UV-B in XXXX .

answer: @entity4


abstract: INTRODUCTION: @entity5 ( @entity5 ) is reported from nearly all geographic areas of Bangladesh, but little information is available on its epidemiologic and clinical features. The aim of this study was to describe the clinical manifestations of hepatic and abdominal @entity5 cases presenting to tertiary referral hospitals in Dhaka, Bangladesh. METHODOLOGY: A retrospective study was conducted via chart reviews of hepatic and abdominal @entity5 @entity0 under care at tertiary referral hospitals in Dhaka, Bangladesh, between 2002 and 2011. Age, sex, education level, occupation, urban versus rural residence, drinking water source, history of @entity2 ownership, cyst type and location, and clinical manifestations were recorded for all @entity0 . RESULTS: Of the 130 @entity0 enrolled, 92 (70.8%) were female and 38 (29.2%) were male. The majority of @entity0 were from rural (76.2%) rather than urban (23.8%) areas. All cases were from the northern part of the country, with no cases reported from the south or southeast. Most @entity0 were between 21 and 40 years of age. A total of 119 @entity0 (91.5%) had cysts only in the liver, with the remaining 8.5% having cysts in both the liver and lungs or in the abdominal cavity. Seventy-six (58.5%) of the @entity1 were stage @entity4 , indicating @entity3 . CONCLUSIONS: Active transmission of @entity6 appears to be occurring in Bangladesh, as indicated by the high number of @entity4 @entity1 seen at tertiary care hospitals. Community ultrasound screening studies are warranted to better define the distribution of cases and risk factors for parasite transmission.

title: Abdominal XXXX in Bangladesh: a hospital-based study.

answer: @entity5


abstract: PURPOSE: To report on long-term visual outcomes in @entity0 receiving continuous fixed-interval dosing of @entity1 ( @entity1 ) treatment in neovascular @entity3 ( @entity3 ). DESIGN: Single-practice retrospective chart review. @entity0 : One hundred nine eyes with exudative @entity3 receiving continuous fixed-interval dosing (every 4-8 weeks) of anti- @entity1 therapy (ranibizumab, bevacizumab, or aflibercept) for at least 5 years. Eyes were excluded if they averaged fewer than 6.5 injections per year. METHODS: Snellen @entity2 was recorded at baseline and all subsequent injections. Changes from baseline were calculated at yearly intervals. MAIN OUTCOME MEASURES: The primary outcome measure was mean change in letter score at 5, 6, and 7 years; secondary outcomes included the percentage of @entity0 with 20/40 vision or better at 7 years and the mean change in letter score at each yearly time point based on baseline visual grouping (20/40 or better, 20/50-20/100, 20/200 or worse). RESULTS: Forty-four, 75, and 109 @entity0 with 7, 6, and 5 years, respectively, of continuous treatment were identified. Mean change in letter score at year 5 was  +14.0 letters (P  = 3.9  * 10(-9)),  +12.2 letters at 6 years (P  =  1.5  * 10(-7)), and  +12.1 letters at 7 years (P  = 3.8  * 10(-5)). Driving vision (20/40 or better) was achieved in 43.2% of treated eyes. Subanalysis revealed that the greatest visual gains at 5 and 7 years were seen in those @entity0 with baseline @entity2 worse than 20/200 (+24.5 and  +25.5 letters), followed by those with 20/50 to 20/100 vision (+6.7 and  +6.9 letters), and finally those with 20/20 to 20/40 (+3.7 and  +3.4 letters). @entity0 received an average of 10.5 injections per year. CONCLUSIONS: Continuous fixed-interval dosing of anti- @entity1 therapy in @entity0 with exudative @entity3 results in favorable long-term preservation out to 7 years, with vision stabilizing or improving in 93.2% of eyes. Additionally, 43.2% of @entity0 maintained driving vision in the treatment eye at 7 years compared with 10.1% at baseline. Our data suggest better outcomes with continuous therapy over published results with sporadic, as-needed therapy.

title: Long-Term Outcomes in Eyes Receiving Fixed-Interval Dosing of Anti- XXXX Agents for Wet Age-Related @entity3 .

answer: @entity1


abstract: PURPOSE: To report on long-term visual outcomes in @entity0 receiving continuous fixed-interval dosing of @entity1 ( @entity1 ) treatment in neovascular @entity3 ( @entity3 ). DESIGN: Single-practice retrospective chart review. @entity0 : One hundred nine eyes with exudative @entity3 receiving continuous fixed-interval dosing (every 4-8 weeks) of anti- @entity1 therapy (ranibizumab, bevacizumab, or aflibercept) for at least 5 years. Eyes were excluded if they averaged fewer than 6.5 injections per year. METHODS: Snellen @entity2 was recorded at baseline and all subsequent injections. Changes from baseline were calculated at yearly intervals. MAIN OUTCOME MEASURES: The primary outcome measure was mean change in letter score at 5, 6, and 7 years; secondary outcomes included the percentage of @entity0 with 20/40 vision or better at 7 years and the mean change in letter score at each yearly time point based on baseline visual grouping (20/40 or better, 20/50-20/100, 20/200 or worse). RESULTS: Forty-four, 75, and 109 @entity0 with 7, 6, and 5 years, respectively, of continuous treatment were identified. Mean change in letter score at year 5 was  +14.0 letters (P  = 3.9  * 10(-9)),  +12.2 letters at 6 years (P  =  1.5  * 10(-7)), and  +12.1 letters at 7 years (P  = 3.8  * 10(-5)). Driving vision (20/40 or better) was achieved in 43.2% of treated eyes. Subanalysis revealed that the greatest visual gains at 5 and 7 years were seen in those @entity0 with baseline @entity2 worse than 20/200 (+24.5 and  +25.5 letters), followed by those with 20/50 to 20/100 vision (+6.7 and  +6.9 letters), and finally those with 20/20 to 20/40 (+3.7 and  +3.4 letters). @entity0 received an average of 10.5 injections per year. CONCLUSIONS: Continuous fixed-interval dosing of anti- @entity1 therapy in @entity0 with exudative @entity3 results in favorable long-term preservation out to 7 years, with vision stabilizing or improving in 93.2% of eyes. Additionally, 43.2% of @entity0 maintained driving vision in the treatment eye at 7 years compared with 10.1% at baseline. Our data suggest better outcomes with continuous therapy over published results with sporadic, as-needed therapy.

title: Long-Term Outcomes in Eyes Receiving Fixed-Interval Dosing of Anti- @entity1 Agents for Wet Age-Related XXXX .

answer: @entity3


abstract: UNASSIGNED: Identification of biomarkers used for the prognostic evaluation of @entity2 ( @entity2 ) @entity0 is important. The aim of this study was to evaluate the potential prognostic value of @entity9 , @entity6 , @entity4 , and @entity1 single nucleotide polymorphisms (SNPs) in completely resected @entity2 @entity0 . In total, 130 @entity0 , surgically treated for @entity2 between 2000 and 2012, were included. An analysis of SNPs from peripheral blood cells was performed by polymerase chain reaction. @entity9 @entity10 , @entity6 @entity7 , @entity4 @entity8 , and @entity1 @entity5 polymorphisms were evaluated in conjunction with clinical and pathological parameters and survival. Kaplan-Meier method and Cox regression analysis were used. Median age rate was 59.3, ranging between 36 and 78  years. Median @entity3 ( @entity3 ) was found as 46.2  months. In those with @entity4 CC allele, median @entity3 was detected as 28.3  months (95  % confidence interval (CI), 20.8-35.8), 46.9  months in those with CT heterozygous (95  % CI, 18.6-75.2), and 80.1  months for those with TT mutant allel (95  % CI, 33.0-127.2). Median @entity3 was seen to be longer in mutant group and also statistically significant (P   =   0.018). Additionally, upon evaluating CC normal group with CT   +   TT alleles including mutant alleles, median @entity3 was found as 56.5  months (95  % CI, 24.6-88.4) in CT   +   TT group, and this was statistically significant (P   =   0.005) Also, median @entity3 was 15.1  months in those including @entity4 CC allele and 56.5  months in CT   +   TT allele in the group with no adjuvant treatment (P   =   0.001). In conclusion, our study showed that @entity4 / @entity4 polymorphism is an independent prognostic factor in operated @entity2 @entity0 , and these findings should be supported with prospective studies.

title: Prognostic value of @entity6 , @entity4 , @entity9 , and @entity1 single nucleotide polymorphisms in @entity0 with early-stage XXXX .

answer: @entity2


abstract: UNASSIGNED: Identification of biomarkers used for the prognostic evaluation of @entity2 ( @entity2 ) @entity0 is important. The aim of this study was to evaluate the potential prognostic value of @entity9 , @entity6 , @entity4 , and @entity1 single nucleotide polymorphisms (SNPs) in completely resected @entity2 @entity0 . In total, 130 @entity0 , surgically treated for @entity2 between 2000 and 2012, were included. An analysis of SNPs from peripheral blood cells was performed by polymerase chain reaction. @entity9 @entity10 , @entity6 @entity7 , @entity4 @entity8 , and @entity1 @entity5 polymorphisms were evaluated in conjunction with clinical and pathological parameters and survival. Kaplan-Meier method and Cox regression analysis were used. Median age rate was 59.3, ranging between 36 and 78  years. Median @entity3 ( @entity3 ) was found as 46.2  months. In those with @entity4 CC allele, median @entity3 was detected as 28.3  months (95  % confidence interval (CI), 20.8-35.8), 46.9  months in those with CT heterozygous (95  % CI, 18.6-75.2), and 80.1  months for those with TT mutant allel (95  % CI, 33.0-127.2). Median @entity3 was seen to be longer in mutant group and also statistically significant (P   =   0.018). Additionally, upon evaluating CC normal group with CT   +   TT alleles including mutant alleles, median @entity3 was found as 56.5  months (95  % CI, 24.6-88.4) in CT   +   TT group, and this was statistically significant (P   =   0.005) Also, median @entity3 was 15.1  months in those including @entity4 CC allele and 56.5  months in CT   +   TT allele in the group with no adjuvant treatment (P   =   0.001). In conclusion, our study showed that @entity4 / @entity4 polymorphism is an independent prognostic factor in operated @entity2 @entity0 , and these findings should be supported with prospective studies.

title: Prognostic value of @entity6 , @entity4 , @entity9 , and XXXX single nucleotide polymorphisms in @entity0 with early-stage @entity2 .

answer: @entity1


abstract: UNASSIGNED: Identification of biomarkers used for the prognostic evaluation of @entity2 ( @entity2 ) @entity0 is important. The aim of this study was to evaluate the potential prognostic value of @entity9 , @entity6 , @entity4 , and @entity1 single nucleotide polymorphisms (SNPs) in completely resected @entity2 @entity0 . In total, 130 @entity0 , surgically treated for @entity2 between 2000 and 2012, were included. An analysis of SNPs from peripheral blood cells was performed by polymerase chain reaction. @entity9 @entity10 , @entity6 @entity7 , @entity4 @entity8 , and @entity1 @entity5 polymorphisms were evaluated in conjunction with clinical and pathological parameters and survival. Kaplan-Meier method and Cox regression analysis were used. Median age rate was 59.3, ranging between 36 and 78  years. Median @entity3 ( @entity3 ) was found as 46.2  months. In those with @entity4 CC allele, median @entity3 was detected as 28.3  months (95  % confidence interval (CI), 20.8-35.8), 46.9  months in those with CT heterozygous (95  % CI, 18.6-75.2), and 80.1  months for those with TT mutant allel (95  % CI, 33.0-127.2). Median @entity3 was seen to be longer in mutant group and also statistically significant (P   =   0.018). Additionally, upon evaluating CC normal group with CT   +   TT alleles including mutant alleles, median @entity3 was found as 56.5  months (95  % CI, 24.6-88.4) in CT   +   TT group, and this was statistically significant (P   =   0.005) Also, median @entity3 was 15.1  months in those including @entity4 CC allele and 56.5  months in CT   +   TT allele in the group with no adjuvant treatment (P   =   0.001). In conclusion, our study showed that @entity4 / @entity4 polymorphism is an independent prognostic factor in operated @entity2 @entity0 , and these findings should be supported with prospective studies.

title: Prognostic value of XXXX , @entity4 , @entity9 , and @entity1 single nucleotide polymorphisms in @entity0 with early-stage @entity2 .

answer: @entity6


abstract: UNASSIGNED: Identification of biomarkers used for the prognostic evaluation of @entity2 ( @entity2 ) @entity0 is important. The aim of this study was to evaluate the potential prognostic value of @entity9 , @entity6 , @entity4 , and @entity1 single nucleotide polymorphisms (SNPs) in completely resected @entity2 @entity0 . In total, 130 @entity0 , surgically treated for @entity2 between 2000 and 2012, were included. An analysis of SNPs from peripheral blood cells was performed by polymerase chain reaction. @entity9 @entity10 , @entity6 @entity7 , @entity4 @entity8 , and @entity1 @entity5 polymorphisms were evaluated in conjunction with clinical and pathological parameters and survival. Kaplan-Meier method and Cox regression analysis were used. Median age rate was 59.3, ranging between 36 and 78  years. Median @entity3 ( @entity3 ) was found as 46.2  months. In those with @entity4 CC allele, median @entity3 was detected as 28.3  months (95  % confidence interval (CI), 20.8-35.8), 46.9  months in those with CT heterozygous (95  % CI, 18.6-75.2), and 80.1  months for those with TT mutant allel (95  % CI, 33.0-127.2). Median @entity3 was seen to be longer in mutant group and also statistically significant (P   =   0.018). Additionally, upon evaluating CC normal group with CT   +   TT alleles including mutant alleles, median @entity3 was found as 56.5  months (95  % CI, 24.6-88.4) in CT   +   TT group, and this was statistically significant (P   =   0.005) Also, median @entity3 was 15.1  months in those including @entity4 CC allele and 56.5  months in CT   +   TT allele in the group with no adjuvant treatment (P   =   0.001). In conclusion, our study showed that @entity4 / @entity4 polymorphism is an independent prognostic factor in operated @entity2 @entity0 , and these findings should be supported with prospective studies.

title: Prognostic value of @entity6 , XXXX , @entity9 , and @entity1 single nucleotide polymorphisms in @entity0 with early-stage @entity2 .

answer: @entity4


abstract: UNASSIGNED: Identification of biomarkers used for the prognostic evaluation of @entity2 ( @entity2 ) @entity0 is important. The aim of this study was to evaluate the potential prognostic value of @entity9 , @entity6 , @entity4 , and @entity1 single nucleotide polymorphisms (SNPs) in completely resected @entity2 @entity0 . In total, 130 @entity0 , surgically treated for @entity2 between 2000 and 2012, were included. An analysis of SNPs from peripheral blood cells was performed by polymerase chain reaction. @entity9 @entity10 , @entity6 @entity7 , @entity4 @entity8 , and @entity1 @entity5 polymorphisms were evaluated in conjunction with clinical and pathological parameters and survival. Kaplan-Meier method and Cox regression analysis were used. Median age rate was 59.3, ranging between 36 and 78  years. Median @entity3 ( @entity3 ) was found as 46.2  months. In those with @entity4 CC allele, median @entity3 was detected as 28.3  months (95  % confidence interval (CI), 20.8-35.8), 46.9  months in those with CT heterozygous (95  % CI, 18.6-75.2), and 80.1  months for those with TT mutant allel (95  % CI, 33.0-127.2). Median @entity3 was seen to be longer in mutant group and also statistically significant (P   =   0.018). Additionally, upon evaluating CC normal group with CT   +   TT alleles including mutant alleles, median @entity3 was found as 56.5  months (95  % CI, 24.6-88.4) in CT   +   TT group, and this was statistically significant (P   =   0.005) Also, median @entity3 was 15.1  months in those including @entity4 CC allele and 56.5  months in CT   +   TT allele in the group with no adjuvant treatment (P   =   0.001). In conclusion, our study showed that @entity4 / @entity4 polymorphism is an independent prognostic factor in operated @entity2 @entity0 , and these findings should be supported with prospective studies.

title: Prognostic value of @entity6 , @entity4 , XXXX , and @entity1 single nucleotide polymorphisms in @entity0 with early-stage @entity2 .

answer: @entity9


abstract: UNASSIGNED: Identification of biomarkers used for the prognostic evaluation of @entity2 ( @entity2 ) @entity0 is important. The aim of this study was to evaluate the potential prognostic value of @entity9 , @entity6 , @entity4 , and @entity1 single nucleotide polymorphisms (SNPs) in completely resected @entity2 @entity0 . In total, 130 @entity0 , surgically treated for @entity2 between 2000 and 2012, were included. An analysis of SNPs from peripheral blood cells was performed by polymerase chain reaction. @entity9 @entity10 , @entity6 @entity7 , @entity4 @entity8 , and @entity1 @entity5 polymorphisms were evaluated in conjunction with clinical and pathological parameters and survival. Kaplan-Meier method and Cox regression analysis were used. Median age rate was 59.3, ranging between 36 and 78  years. Median @entity3 ( @entity3 ) was found as 46.2  months. In those with @entity4 CC allele, median @entity3 was detected as 28.3  months (95  % confidence interval (CI), 20.8-35.8), 46.9  months in those with CT heterozygous (95  % CI, 18.6-75.2), and 80.1  months for those with TT mutant allel (95  % CI, 33.0-127.2). Median @entity3 was seen to be longer in mutant group and also statistically significant (P   =   0.018). Additionally, upon evaluating CC normal group with CT   +   TT alleles including mutant alleles, median @entity3 was found as 56.5  months (95  % CI, 24.6-88.4) in CT   +   TT group, and this was statistically significant (P   =   0.005) Also, median @entity3 was 15.1  months in those including @entity4 CC allele and 56.5  months in CT   +   TT allele in the group with no adjuvant treatment (P   =   0.001). In conclusion, our study showed that @entity4 / @entity4 polymorphism is an independent prognostic factor in operated @entity2 @entity0 , and these findings should be supported with prospective studies.

title: Prognostic value of @entity6 , @entity4 , @entity9 , and @entity1 single nucleotide polymorphisms in XXXX with early-stage @entity2 .

answer: @entity0


abstract: Eighty successive @entity0 underwent the Mustard operation for "simple" @entity6 (TGA) between January, 1970, and January, 1980. Ages ranged from 42 days to 12.4 years (mean 14.7 months). Balloon atrial septostomy (BAS) with balloon volumes of more than 2.5 ml produced significant increases of arterial @entity1 saturation, although the initial benefit of BAS was greater than that found at follow-up catheterization. In these @entity0 the left ventricular (LV) pressure tended to decrease during the first months of life, but this drop was less marked at the end of the first year. Deep @entity4 and @entity3 were employed in all cases. Several modifications were adapted to the original surgical technique in order to reduce last sequelae. There were two early and three late deaths. At follow-up (mean 4.5 years) 74% of @entity0 were symptom free. Sinoatrial and atrioventricular (AV) conduction disturbances were present in five and six @entity0 , respectively. Caval or @entity5 occurred in 13 @entity0 , seven of whom required reoperation. Isolated @entity2 was present in one @entity0 only, but in four it was associated with other defects. Primary right ventricular (RV) failure occurred in one @entity0 . These findings, in relation to mortality, complications, and the excellent clinical results in the majority of survivors, compare favorably with results published for @entity0 with "simple" TGA who have been subjected to other types of physiological or anatomic correction. At the present time, there seems to be no good reason to alter our surgical policy in this group of @entity0 .

title: Appraisal of the Mustard procedure for the physiological correction of "simple" XXXX . Eighty consecutive cases, 1970-1980.

answer: @entity6


abstract: Between 1971 and 1980, 20 @entity0 with @entity1 were treated by resection of ventricular endocardium and replacement of the @entity3 . There were 13 male and seven female @entity0 whose ages ranged between 12 and 58 years. Thirteen were white and the remaining seven were black Africans. Nine presented a right-sided form, five a left-sided one, and six presented involvement of both ventricles. The role of @entity6 is discussed in the etiology of the disease. The operation was performed according to the techniques we had developed in our first operative case-excision of the @entity3 . Complete resection of the endocardium, and valvular replacement. There were three operative @entity2 . Complete @entity4 was observed in seven of our @entity0 . particularly in those with right-sided @entity5 . At late follow-up, we have not observed any case of recurrence of the disease. On the basis of our experience and the results previously published in the literature, we believe that endocardiectomy is the best current treatment of this disease.

title: Surgical treatment of constrictive XXXX .

answer: @entity1


abstract: In this study, we retrospectively analyzed the outcomes of adults with @entity3 who underwent @entity2 ( @entity2 ), consisting of replacement of the diseased BAV with 2 or 3 pericardial leaflets plus fixation of the sinotubular junction for accurate and constant leaflet coaptation. From December 2007 through April 2013, 135 consecutive @entity0 (mean age, 49.2    13.1 yr; 73.3% @entity0 ) with symptomatic @entity3 underwent @entity2 . Raphe was observed in 84 @entity0 (62.2%), and the remaining 51 @entity0 had pure BAV without raphe. A total of 122 @entity0 (90.4%) underwent 3-leaflet reconstruction, and 13 (9.6%) underwent 2-leaflet reconstruction. Concomitant aortic wrapping with an artificial graft was performed in 63 @entity0 (46.7%). There were no in-hospital deaths and 2 late deaths (1.5%); 6 @entity0 (4.4%) needed valve-related reoperation. The 5-year cumulative survival rate was 98%    1.5%, and freedom from valve-related reoperation at 5 years was 92.7%    3.6%. In the last available echocardiograms, @entity1 was absent or trivial in 116 @entity0 (85.9%), mild in 16 (11.9%), moderate in 2 (1.5%), and severe in one (0.7%). The mean aortic valve gradient was 10.2    4.5 mmHg, and the mean aortic valve orifice area index was 1.3    0.3 cm(2)/m(2). The 3-leaflet technique resulted in lower valve gradients and greater valve areas than did the 2-leaflet technique. Thus, in @entity0 with BAV, @entity2 yielded satisfactory early and midterm results with low mortality rates and low reoperation risk after the initial procedure.

title: Aortic valve reconstruction with use of pericardial leaflets in adults with bicuspid XXXX : early and midterm outcomes.

answer: @entity2


abstract: INTRODUCTION: Hydatid cyst is a significant health problem in underdeveloped and developing countries, particularly among @entity5 breeders. Although @entity3 is seen only in 0.2% to 3% of the cases, early diagnosis and treatment are important. CASE PRESENTATION: A 13-year-old @entity0 with @entity6 and atypical pericardial type @entity4 for three months was referred to us. Chest X-ray revealed linear calcification in the left side of the heart. Computed tomography demonstrated a cyst with peripheral calcification and without internal septation in the lateral left ventricle (LV) myocardium. Serologic IgG test was positive for @entity7 . No other cyst was seen in the other organs such as the lungs and liver. By midline sternotomy on pump, an incision was made 2-cm lateral to the left ascending artery through the LV myocardium and without entering any cardiac chamber. After injecting hypertonic (5%) saline, the cyst was punctured and its fluid contents were aspirated, the cyst was enucleated, and the cavity marsupialization was done for protection of the myocardium. LV ejection fraction before operation was 40% but after operation and repairing LV myocardium, ejection fraction increased to 50% in. Histopathologic examination confirmed a hydatid cyst. CONCLUSIONS: In myocardial hydatid cysts, we recommend a direct approach without entering the cardiac chambers to avoid dissemination of the @entity1 . We recommend excision of the germinative membrane without capitonnage to avoid impairment of @entity2 .

title: Heart hydatid cyst close to the left descending artery in a thirteen-year-old XXXX .

answer: @entity0


abstract: BACKGROUND: @entity4 ( @entity4 ) are benign, highly vascularized lesions located in the jugular foramen with frequent invasion to the temporal bone, the upper neck, and the posterior fossa cavity. Their natural history, surgical treatment, and outcome have been well addressed in the recent literature; however, there is no consensus regarding the optimal management while minimizing treatment-related morbidity. In this study, we assessed the interdisciplinary microsurgical treatment and outcome of large TJP collected at a single center. METHODS: Out of 54 @entity0 with skull base @entity4 , 14 (25%) presented with large TJP (Fisch grade C and D). Posterior fossa involvement was present in 10 @entity0 (Fisch D). Eleven @entity0 presented with @entity3 , two @entity0 with mild @entity5 , and two @entity0 with lower @entity2 . Two other @entity0 with previous surgery presented with @entity1 regrowth. RESULTS: Preoperative embolization was performed in 13 cases. @entity1 removal was possible in 10 @entity0 . Hearing was preserved in four @entity0 with normal preoperative audiogram. The facial nerve was preserved in all @entity0 . Temporary @entity5 occurred in two @entity0 and resolved in long-term follow-up. In three @entity0 , preexisting @entity5 remained unchanged. Persistent @entity6 was present in three @entity0 and was treated with laryngoplasty. The global recovery based on the Karnofsky performance scale was 100% in 10 @entity0 and 90% in 4 @entity0 . CONCLUSION: Preoperative embolization and interdisciplinary microsurgical resection are the preferred treatment for selected @entity0 due to high @entity1 control rates and good long-term results.

title: Microsurgical treatment of large and XXXX .

answer: @entity4


abstract: INTRODUCTION: @entity2 is a serious condition affecting up to 50% of Indian postmenopausal @entity0 . Denosumab reduces bone resorption by targeting the receptor activator of nuclear factor-kB ligand. This study assessed the efficacy and safety of denosumab in Indian postmenopausal @entity0 with @entity2 . MATERIALS AND METHODS: In this double-blind, multicenter, phase 3 study, 250 Indian postmenopausal @entity0 aged 55 to 75 years (T-score <-2.5 and >-4.0 at the lumbar spine or total hip; serum 25(OH) D levels >= 20 ng/mL) were randomized to receive one subcutaneous dose of denosumab 60 mg or placebo. All subjects received oral calcium >= 1000 mg and vitamin D3 >=  400 IU daily. The primary end point was mean percent change in @entity1 ( @entity1 ) at the lumbar spine from baseline to Month 6. Secondary end points included mean percent change from baseline in @entity1 , and trochanter at Month 6 and median percent change from baseline in bone turnover markers at Months 1, 3, and 6. RESULTS: Total 225 subjects (denosumab = 111, placebo = 114) completed the six-month study. Baseline demographics were similar between groups. A 3.1% (95% confidence interval, 1.9%, 4.2%) increase favoring denosumab versus placebo was seen for the primary end point (P < 0.0001). Denosumab demonstrated a significant treatment benefit over placebo for the secondary end points. There were no @entity3 or withdrawals due to adverse events. CONCLUSIONS: Consistent with results from studies conducted in other parts of the world, denosumab was well tolerated and effective in increasing @entity1 and decreasing bone turnover markers over a six-month period in Indian postmenopausal @entity0 .

title: A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal @entity0 with XXXX .

answer: @entity2


abstract: INTRODUCTION: @entity2 is a serious condition affecting up to 50% of Indian postmenopausal @entity0 . Denosumab reduces bone resorption by targeting the receptor activator of nuclear factor-kB ligand. This study assessed the efficacy and safety of denosumab in Indian postmenopausal @entity0 with @entity2 . MATERIALS AND METHODS: In this double-blind, multicenter, phase 3 study, 250 Indian postmenopausal @entity0 aged 55 to 75 years (T-score <-2.5 and >-4.0 at the lumbar spine or total hip; serum 25(OH) D levels >= 20 ng/mL) were randomized to receive one subcutaneous dose of denosumab 60 mg or placebo. All subjects received oral calcium >= 1000 mg and vitamin D3 >=  400 IU daily. The primary end point was mean percent change in @entity1 ( @entity1 ) at the lumbar spine from baseline to Month 6. Secondary end points included mean percent change from baseline in @entity1 , and trochanter at Month 6 and median percent change from baseline in bone turnover markers at Months 1, 3, and 6. RESULTS: Total 225 subjects (denosumab = 111, placebo = 114) completed the six-month study. Baseline demographics were similar between groups. A 3.1% (95% confidence interval, 1.9%, 4.2%) increase favoring denosumab versus placebo was seen for the primary end point (P < 0.0001). Denosumab demonstrated a significant treatment benefit over placebo for the secondary end points. There were no @entity3 or withdrawals due to adverse events. CONCLUSIONS: Consistent with results from studies conducted in other parts of the world, denosumab was well tolerated and effective in increasing @entity1 and decreasing bone turnover markers over a six-month period in Indian postmenopausal @entity0 .

title: A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal XXXX with @entity2 .

answer: @entity0


abstract: Empagliflozin is agent of new antidiabetic drugs that cause @entity7 blocking the @entity8 reuptake in the proxi-mal tubule. The loss of 50-100 g of @entity8 / 24 hours in the urine results in a reduction of fasting @entity8 , especially post-prandial @entity8 , the energy expenditure of 200-400 kcal / day and blood pressure lowering. Treatment efficacy does not decrease over time, as it is not dependent on its own insulin production. The work evaluates the safety of modern treatment with empagliflozin which will soon appear in the portfolio of antidiabetic agents in the Czech Republic. The conducted studies with a special focus on empagliflozin treatment have shown high efficacy, safety and good tolerability of drug. It has been described a higher incidence of @entity2 with non-severe course, especially in @entity0 . The drug does not cause hypoglycaemia. In combination with sulfonylurea hypoglycaemia may occur. Empagliflozin does not cause clinically significant @entity6 or @entity5 in @entity0 about 60 years of age, but some caution in empagliflozin treatment should be in elderly and fragile @entity0 . The big convenience of empagliflozin is its clinically non-significant interactions with other drugs and simple dosage of 1 tablet / day orally. In conclusion, empagliflozin is highly effective oral antidiabetic agent with a potential of wide application in all stages of type 2 @entity1 in monotherapy or combined with other medication. The treatment is associated with @entity3 and blood pressure lowering. The drug is effective and safe until @entity4 45 ml / s, in lower values the treatment should be discontinued. The occurrence of side effects is rare, except increased incidence of @entity2 especially in @entity0 and increased risk of hypoglycaemia when empagliflozin is combined with sulfonylurea.Key words: @entity1 treatment - empagliflozin - HbA1c - @entity9 .

title: [New XXXX inhibitor empagliflozin: modern and safe treatment of  @entity1 ].

answer: @entity9


abstract: Empagliflozin is agent of new antidiabetic drugs that cause @entity7 blocking the @entity8 reuptake in the proxi-mal tubule. The loss of 50-100 g of @entity8 / 24 hours in the urine results in a reduction of fasting @entity8 , especially post-prandial @entity8 , the energy expenditure of 200-400 kcal / day and blood pressure lowering. Treatment efficacy does not decrease over time, as it is not dependent on its own insulin production. The work evaluates the safety of modern treatment with empagliflozin which will soon appear in the portfolio of antidiabetic agents in the Czech Republic. The conducted studies with a special focus on empagliflozin treatment have shown high efficacy, safety and good tolerability of drug. It has been described a higher incidence of @entity2 with non-severe course, especially in @entity0 . The drug does not cause hypoglycaemia. In combination with sulfonylurea hypoglycaemia may occur. Empagliflozin does not cause clinically significant @entity6 or @entity5 in @entity0 about 60 years of age, but some caution in empagliflozin treatment should be in elderly and fragile @entity0 . The big convenience of empagliflozin is its clinically non-significant interactions with other drugs and simple dosage of 1 tablet / day orally. In conclusion, empagliflozin is highly effective oral antidiabetic agent with a potential of wide application in all stages of type 2 @entity1 in monotherapy or combined with other medication. The treatment is associated with @entity3 and blood pressure lowering. The drug is effective and safe until @entity4 45 ml / s, in lower values the treatment should be discontinued. The occurrence of side effects is rare, except increased incidence of @entity2 especially in @entity0 and increased risk of hypoglycaemia when empagliflozin is combined with sulfonylurea.Key words: @entity1 treatment - empagliflozin - HbA1c - @entity9 .

title: [New @entity9 inhibitor empagliflozin: modern and safe treatment of  XXXX ].

answer: @entity1


abstract: UNASSIGNED: Treatment initiation rates following @entity3 have often been reported to be low and in recent years numerous programs have been implemented worldwide to increase them. This study aimed at describing @entity1 ( @entity1 ) treatment initiation in a representative sample of @entity0 who were hospitalized for a @entity3 ( @entity3 ) or @entity3 ( @entity3 ) in 2009-2011 in France. The data source was a nationwide sample of 600,000 individuals, extracted from the French National Insurance Healthcare System database. All @entity0 aged 50 years and older who were hospitalized for a @entity3 or @entity3 between 2009 and 2011 and who had not received any @entity1 treatment in the preceding 12 months were included in a retrospective cohort study. @entity1 treatments initiated during the year following the @entity3 were analyzed. From 2009 to 2011, 729 @entity0 were hospitalized for a @entity3 or a @entity3 and 284 were on @entity1 treatment at the time of the @entity3 occurrence. Among the 445 @entity0 who had no prevalent @entity1 treatment, 131 (29.4%) received supplementation treatment only ( @entity7 and/or @entity6 ) and 42 (9.4%) received a pharmacologic @entity1 treatment in the year following their @entity3 . Pharmacological @entity1 treatments included @entity2 (n = 21), @entity4 (n = 14), hormone replacement therapy (n = 4), or @entity5 (n = 3). General practitioners prescribed 75% of initial @entity1 treatments. Despite the guidelines published in 2006 and the numerous initiatives to promote post- @entity3 @entity1 treatment, @entity1 treatment initiation rate in @entity0 who were hospitalized for a @entity3 remained low in 2009-2011 in France.

title: Low XXXX Treatment Initiation Rate in @entity0 after Distal Forearm or Proximal Humerus Fracture: A Healthcare Database Nested Cohort Study.

answer: @entity1


abstract: UNASSIGNED: Treatment initiation rates following @entity3 have often been reported to be low and in recent years numerous programs have been implemented worldwide to increase them. This study aimed at describing @entity1 ( @entity1 ) treatment initiation in a representative sample of @entity0 who were hospitalized for a @entity3 ( @entity3 ) or @entity3 ( @entity3 ) in 2009-2011 in France. The data source was a nationwide sample of 600,000 individuals, extracted from the French National Insurance Healthcare System database. All @entity0 aged 50 years and older who were hospitalized for a @entity3 or @entity3 between 2009 and 2011 and who had not received any @entity1 treatment in the preceding 12 months were included in a retrospective cohort study. @entity1 treatments initiated during the year following the @entity3 were analyzed. From 2009 to 2011, 729 @entity0 were hospitalized for a @entity3 or a @entity3 and 284 were on @entity1 treatment at the time of the @entity3 occurrence. Among the 445 @entity0 who had no prevalent @entity1 treatment, 131 (29.4%) received supplementation treatment only ( @entity7 and/or @entity6 ) and 42 (9.4%) received a pharmacologic @entity1 treatment in the year following their @entity3 . Pharmacological @entity1 treatments included @entity2 (n = 21), @entity4 (n = 14), hormone replacement therapy (n = 4), or @entity5 (n = 3). General practitioners prescribed 75% of initial @entity1 treatments. Despite the guidelines published in 2006 and the numerous initiatives to promote post- @entity3 @entity1 treatment, @entity1 treatment initiation rate in @entity0 who were hospitalized for a @entity3 remained low in 2009-2011 in France.

title: Low @entity1 Treatment Initiation Rate in XXXX after Distal Forearm or Proximal Humerus Fracture: A Healthcare Database Nested Cohort Study.

answer: @entity0


abstract: UNASSIGNED: Kalanchoe crenata popularly known as " @entity3 's liver" is used in most African countries for the treatment of @entity2 such as @entity1 , @entity5 and @entity6 / @entity7 related @entity4 . The evaluation of K. crenata for herb-drug interactions has not been reported. This study therefore aims to evaluate the risk of K. crenata for herb-drug interaction in vitro. Crude @entity8 and fractions of K. crenata were incubated and preincubated with recombinant @entity0 @entity9 and @entity10 . Comparative studies were conducted in both @entity0 liver microsomes and recombinant @entity0 CYP to ascertain the inhibition profile of the crude extract and the various fractions. The cocktail approach of recombinant @entity0 CYPs was conducted to confirm the inhibition potential of the fractions in the presence of other CYPs. The results showed significant time-dependent inhibition of tested samples on @entity10 with crude @entity8 (39KC), fractions 45A, 45B and 45D given IC50 fold decrease of 3.29, 2.26, 1.91 and 1.49 respective. Time dependent kinetic assessment of 39KC and 45D showed KI and kinact values for 39KC as 1.77 g/mL and 0.091 min-1 while that of 45D were 6.45  g/mL and 0.024 min-1 respectively. Determination of kinact based on IC50 calculations yielded 0.015 and 0.04 min-1 for 39KC and 45D respectively. Cocktail approach exhibited fold decreases in IC50 for all test fractions on @entity10 within the ranges of 2.10 - 4.10. At least one phytoconstituent in the crude @entity8 extract of Kalanchoe crenata is a reversible and time-dependent inhibitor of @entity10 .

title: In Vitro Evaluation of Reversible and Time-Dependent Inhibitory Effects of Kalanchoe Crenata on XXXX and @entity10 Activity.

answer: @entity9


abstract: UNASSIGNED: Kalanchoe crenata popularly known as " @entity3 's liver" is used in most African countries for the treatment of @entity2 such as @entity1 , @entity5 and @entity6 / @entity7 related @entity4 . The evaluation of K. crenata for herb-drug interactions has not been reported. This study therefore aims to evaluate the risk of K. crenata for herb-drug interaction in vitro. Crude @entity8 and fractions of K. crenata were incubated and preincubated with recombinant @entity0 @entity9 and @entity10 . Comparative studies were conducted in both @entity0 liver microsomes and recombinant @entity0 CYP to ascertain the inhibition profile of the crude extract and the various fractions. The cocktail approach of recombinant @entity0 CYPs was conducted to confirm the inhibition potential of the fractions in the presence of other CYPs. The results showed significant time-dependent inhibition of tested samples on @entity10 with crude @entity8 (39KC), fractions 45A, 45B and 45D given IC50 fold decrease of 3.29, 2.26, 1.91 and 1.49 respective. Time dependent kinetic assessment of 39KC and 45D showed KI and kinact values for 39KC as 1.77 g/mL and 0.091 min-1 while that of 45D were 6.45  g/mL and 0.024 min-1 respectively. Determination of kinact based on IC50 calculations yielded 0.015 and 0.04 min-1 for 39KC and 45D respectively. Cocktail approach exhibited fold decreases in IC50 for all test fractions on @entity10 within the ranges of 2.10 - 4.10. At least one phytoconstituent in the crude @entity8 extract of Kalanchoe crenata is a reversible and time-dependent inhibitor of @entity10 .

title: In Vitro Evaluation of Reversible and Time-Dependent Inhibitory Effects of Kalanchoe Crenata on @entity9 and XXXX Activity.

answer: @entity10


abstract: One hundred and sixty-three @entity0 subjected to three different types of thoracic operation were allocated randomly either to balanced intravenous anaesthesia including i.v. opiates with post-operative intramuscular opiates (intramuscular group) or to balanced intravenous anaesthesia without i.v. opiates but with high thoracic epidural regional block during the operation as well as epidural @entity3 post-operatively (epidural group). Post-operative @entity3 was given only at the request of the @entity0 and as frequently as needed to obtain satisfactory @entity1 relief. @entity0 in the epidural group received @entity3 exclusively by epidural injection. In this paper (Part I), general parameters between the epidural group and the im. group are compared. The epidural group showed acceptable cardiovascular stability during the operation. With the catheter tip at the T3-T4 level, there was apparently a preferential spread downwards of the local anaesthetics. Post-operatively both groups (i.m. and epidural) provided effective and rapid onset of @entity2 . There were no major differences in post-operative @entity1 assessment, either by the @entity0 or by the team.

title: Post-operative @entity2 by epidural versus intramuscular XXXX after thoracotomy. Part I.

answer: @entity3


abstract: One hundred and sixty-three @entity0 subjected to three different types of thoracic operation were allocated randomly either to balanced intravenous anaesthesia including i.v. opiates with post-operative intramuscular opiates (intramuscular group) or to balanced intravenous anaesthesia without i.v. opiates but with high thoracic epidural regional block during the operation as well as epidural @entity3 post-operatively (epidural group). Post-operative @entity3 was given only at the request of the @entity0 and as frequently as needed to obtain satisfactory @entity1 relief. @entity0 in the epidural group received @entity3 exclusively by epidural injection. In this paper (Part I), general parameters between the epidural group and the im. group are compared. The epidural group showed acceptable cardiovascular stability during the operation. With the catheter tip at the T3-T4 level, there was apparently a preferential spread downwards of the local anaesthetics. Post-operatively both groups (i.m. and epidural) provided effective and rapid onset of @entity2 . There were no major differences in post-operative @entity1 assessment, either by the @entity0 or by the team.

title: Post-operative XXXX by epidural versus intramuscular @entity3 after thoracotomy. Part I.

answer: @entity2